Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
23 Mar 2023
Historique:
received: 27 09 2022
accepted: 27 02 2023
entrez: 23 3 2023
pubmed: 24 3 2023
medline: 24 3 2023
Statut: epublish

Résumé

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral vector encoding RSV preF protein (Ad26.RSV.preF) are immunogenic and protective in animals when administered as single components. Here, we evaluated a combination of the 2 components, administered as a single injection. Strong induction of both humoral and cellular responses was shown in RSV-naïve and pre-exposed mice and pre-exposed African green monkeys (AGMs). Both components of the combination vaccine contributed to humoral immune responses, while the Ad26.RSV.preF component was the main contributor to cellular immune responses in both mice and AGMs. Immunization with the combination elicited superior protection against RSV A2 challenge in cotton rats. These results demonstrate the advantage of a combination vaccine and support further clinical development.

Identifiants

pubmed: 36949051
doi: 10.1038/s41541-023-00637-7
pii: 10.1038/s41541-023-00637-7
pmc: PMC10033289
doi:

Types de publication

Journal Article

Langues

eng

Pagination

45

Subventions

Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : P40-OD010965

Informations de copyright

© 2023. The Author(s).

Références

J Infect. 2019 May;78(5):382-392
pubmed: 30742894
Curr Opin Virol. 2013 Aug;3(4):468-74
pubmed: 23806514
Pediatr Infect Dis J. 2012 Jan;31(1):5-9
pubmed: 21817948
J Infect Dis. 2020 Aug 17;222(6):979-988
pubmed: 32320465
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Cell Host Microbe. 2022 Jan 12;30(1):41-52.e5
pubmed: 34879230
J Infect Dis. 2017 Dec 12;216(11):1362-1370
pubmed: 29029260
Vaccine. 2022 Feb 7;40(6):934-944
pubmed: 34973849
Viral Immunol. 2018 Mar;31(2):195-203
pubmed: 29336703
Vaccines (Basel). 2021 Jun 09;9(6):
pubmed: 34207770
Respir Care. 2003 Mar;48(3):209-31; discussion 231-3
pubmed: 12667273
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
Sci Transl Med. 2015 Oct 14;7(309):309ra162
pubmed: 26468324
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3089-94
pubmed: 22323598
Lancet Respir Med. 2021 Oct;9(10):1111-1120
pubmed: 33864736
J Infect Dis. 2022 Aug 26;226(3):396-406
pubmed: 33400792
NPJ Vaccines. 2020 Jun 12;5(1):49
pubmed: 32566260
J Virol. 2014 Sep;88(18):10354-63
pubmed: 24991003
J Immunol. 2020 Jul 15;205(2):313-320
pubmed: 32493812
Vaccine. 2014 Oct 21;32(46):6130-7
pubmed: 25223272
Clin Infect Dis. 2020 May 6;70(10):2073-2081
pubmed: 31340042
Clin Microbiol Rev. 2000 Jul;13(3):371-84
pubmed: 10885982
Sci Transl Med. 2015 Aug 12;7(300):300ra126
pubmed: 26268313
Vaccine. 2020 Mar 4;38(11):2608-2619
pubmed: 32057576
Mucosal Immunol. 2018 Jan;11(1):249-256
pubmed: 28537249
Vaccine. 2020 Sep 22;38(41):6357-6362
pubmed: 32829976
PLoS One. 2017 Nov 28;12(11):e0188708
pubmed: 29182682
Vaccine. 2017 Jan 11;35(3):489-495
pubmed: 27889256
Open Forum Infect Dis. 2021 Oct 05;8(11):ofab491
pubmed: 35559130
Curr Opin Immunol. 2022 Aug;77:102210
pubmed: 35643023
Immunol Rev. 2019 Mar;288(1):85-96
pubmed: 30874350
J Infect Dis. 1998 Feb;177(2):463-6
pubmed: 9466538
Adv Virol. 2022 Mar 9;2022:8637545
pubmed: 35309598
Science. 2007 Apr 27;316(5824):612-6
pubmed: 17463291
Annu Rev Immunol. 2013;31:443-73
pubmed: 23298205
Front Immunol. 2019 Jul 25;10:1675
pubmed: 31402910
Vaccine. 2017 Feb 1;35(5):757-766
pubmed: 28065474
J Infect Dis. 2022 Apr 19;225(8):1357-1366
pubmed: 34932102
J Infect Dis. 2017 Jan 1;215(1):24-33
pubmed: 27694633
Immunity. 2005 Jul;23(1):41-51
pubmed: 16039578
Nat Commun. 2017 Oct 20;8(1):1085
pubmed: 29057917
J Infect Dis. 2019 Oct 22;220(11):1816-1825
pubmed: 31418022
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
J Clin Invest. 1991 Sep;88(3):1026-33
pubmed: 1909350
Front Immunol. 2020 Jul 17;11:1507
pubmed: 32765520
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Front Immunol. 2019 Mar 22;10:548
pubmed: 30967872
Proc Natl Acad Sci U S A. 1986 Oct;83(19):7462-6
pubmed: 3532115
Vaccine. 2019 May 6;37(20):2694-2703
pubmed: 30987852
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Clin Vaccine Immunol. 2015 Dec 09;23(3):243-5
pubmed: 26656116

Auteurs

Eirikur Saeland (E)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands. ESaeland@its.jnj.com.

Leslie van der Fits (L)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Renske Bolder (R)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Marjolein Heemskerk-van der Meer (M)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Joke Drijver (J)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Yolinda van Polanen (Y)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Cornelis Vaneman (C)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Lisanne Tettero (L)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Freek Cox (F)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Jan Serroyen (J)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Matthew J Jorgensen (MJ)

Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Johannes P M Langedijk (JPM)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Hanneke Schuitemaker (H)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Benoit Callendret (B)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Roland C Zahn (RC)

Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Classifications MeSH